In addition, we show that, by potentiating the chemotherapy-induced tumor suppressor activity of p53, upregulation of ERβ or activation with agonists increases the chemosensitivity of luminal breast cancer cells as it was previously shown with TNBC and lung cancer cells [62, 63]. Here, TP53 is linked to breast carcinoma.